Comparison of Therapies in MS Patients After the First
Demyelinating Event in Real Clinical Practice in the Czech
Republic: Data From the National Registry ReMuS

J 2021

Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS

PAVELEK, Zbysek, Lukas SOBISEK, Jana SARLAKOVA, Pavel POTUZNIK, Marek PETERKA et. al.

Základní údaje

Originální název

Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS

Autoři

PAVELEK, Zbysek (203 Česká republika, garant), Lukas SOBISEK (203 Česká republika), Jana SARLAKOVA (203 Česká republika), Pavel POTUZNIK (203 Česká republika), Marek PETERKA (203 Česká republika), Ivana STETKAROVA (203 Česká republika), Pavel ŠTOURAČ (203 Česká republika, domácí), Jan MARES (203 Česká republika), Pavel HRADILEK (203 Česká republika), Radek AMPAPA (203 Česká republika), Marketa GRUNERMELOVA (203 Česká republika), Marta VACHOVA (203 Česká republika), Eva RECMANOVA (203 Česká republika), Francesco ANGELUCCI, Simona HALUSKOVA (203 Česká republika) a Martin VALIS (203 Česká republika)

Vydání

FRONTIERS IN NEUROLOGY, LAUSANNE, FRONTIERS MEDIA SA, 2021, 1664-2295

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30210 Clinical neurology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.086

Kód RIV

RIV/00216224:14110/21:00121730

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3389/fneur.2020.593527

UT WoS

000611503800001

Klíčová slova anglicky

multiple sclerosis; treatment; long-term therapy; clinical practice; DMD

Štítky

14110221, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 8. 6. 2021 12:44, Mgr. Tereza Miškechová

Anotace

V originále

Background: Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system. Well-established drugs used for MS patients after the first demyelinating event in the Czech Republic include glatiramer acetate (GA), interferon beta-1a (IFN beta-1a), IFN beta-1b (IFN beta-1b), peginterferon beta-1a (peg-IFN beta-1a), and teriflunomide. Objective: The objective of this observational study was to compare the effectiveness of the abovementioned drugs in patients with MS who initiated their therapy after the first demyelinating event. Patients were followed for up to 2 years in real clinical practice in the Czech Republic. Methods: A total of 1,654 MS patients treated after the first demyelinating event and followed up for 2 years were enrolled. Evaluation parameters (endpoints) included the annualized relapse rate (ARR), time to next relapse, change in the Expanded Disability Status Scale (EDSS) score, and time of confirmed disease progression (CDP). When patients ended the therapy before the observational period, the reason for ending the therapy among different treatments was compared. Results: No significant difference was found among the groups of patients treated with IFN beta-1a/1b, GA, or teriflunomide for the following parameters: time to the first relapse, change in the EDSS score, and the proportion of patients with CDP. Compared to IFN beta-1a (44 mcg), a significant increase in the percentage of relapse-free patients was found for GA, but this treatment effect was not confirmed by the validation analysis. Compared to the other drugs, there was a significant difference in the reasons for terminating GA therapy. Conclusion: Small differences were found among GA, IFN beta and teriflunomide therapies, with no significant impact on the final outcome after 2 years. Therefore, in clinical practice, we recommend choosing the drug based on individual potential risk from long-term therapy and on patient preferences and clinical characteristics.

Citovat

PAVELEK, Zbysek, Lukas SOBISEK, Jana SARLAKOVA, Pavel POTUZNIK, Marek PETERKA, Ivana STETKAROVA, Pavel ŠTOURAČ, Jan MARES, Pavel HRADILEK, Radek AMPAPA, Marketa GRUNERMELOVA, Marta VACHOVA, Eva RECMANOVA, Francesco ANGELUCCI, Simona HALUSKOVA a Martin VALIS. Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS. FRONTIERS IN NEUROLOGY. LAUSANNE: FRONTIERS MEDIA SA, 2021, roč. 11, JAN 2021, s. 1-12. ISSN 1664-2295. Dostupné z: https://dx.doi.org/10.3389/fneur.2020.593527.

@article{1774677,
   author = {Pavelek, Zbysek and Sobisek, Lukas and Sarlakova, Jana and Potuznik, Pavel and Peterka, Marek and Stetkarova, Ivana and Štourač, Pavel and Mares, Jan and Hradilek, Pavel and Ampapa, Radek and Grunermelova, Marketa and Vachova, Marta and Recmanova, Eva and Angelucci, Francesco and Haluskova, Simona and Valis, Martin},
   article_location = {LAUSANNE},
   article_number = {JAN 2021},
   doi = {http://dx.doi.org/10.3389/fneur.2020.593527},
   keywords = {multiple sclerosis; treatment; long-term therapy; clinical practice; DMD},
   language = {eng},
   issn = {1664-2295},
   journal = {FRONTIERS IN NEUROLOGY},
   title = {Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS},
   url = {https://www.frontiersin.org/articles/10.3389/fneur.2020.593527/full},
   volume = {11},
   year = {2021}
}

TY  - JOUR
ID  - 1774677
AU  - Pavelek, Zbysek - Sobisek, Lukas - Sarlakova, Jana - Potuznik, Pavel - Peterka, Marek - Stetkarova, Ivana - Štourač, Pavel - Mares, Jan - Hradilek, Pavel - Ampapa, Radek - Grunermelova, Marketa - Vachova, Marta - Recmanova, Eva - Angelucci, Francesco - Haluskova, Simona - Valis, Martin
PY  - 2021
TI  - Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS
JF  - FRONTIERS IN NEUROLOGY
VL  - 11
IS  - JAN 2021
SP  - 1-12
EP  - 1-12
PB  - FRONTIERS MEDIA SA
SN  - 16642295
KW  - multiple sclerosis
KW  - treatment
KW  - long-term therapy
KW  - clinical practice
KW  - DMD
UR  - https://www.frontiersin.org/articles/10.3389/fneur.2020.593527/full
N2  - Background: Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system. Well-established drugs used for MS patients after the first demyelinating event in the Czech Republic include glatiramer acetate (GA), interferon beta-1a (IFN beta-1a), IFN beta-1b (IFN beta-1b), peginterferon beta-1a (peg-IFN beta-1a), and teriflunomide. Objective: The objective of this observational study was to compare the effectiveness of the abovementioned drugs in patients with MS who initiated their therapy after the first demyelinating event. Patients were followed for up to 2 years in real clinical practice in the Czech Republic. Methods: A total of 1,654 MS patients treated after the first demyelinating event and followed up for 2 years were enrolled. Evaluation parameters (endpoints) included the annualized relapse rate (ARR), time to next relapse, change in the Expanded Disability Status Scale (EDSS) score, and time of confirmed disease progression (CDP). When patients ended the therapy before the observational period, the reason for ending the therapy among different treatments was compared. Results: No significant difference was found among the groups of patients treated with IFN beta-1a/1b, GA, or teriflunomide for the following parameters: time to the first relapse, change in the EDSS score, and the proportion of patients with CDP. Compared to IFN beta-1a (44 mcg), a significant increase in the percentage of relapse-free patients was found for GA, but this treatment effect was not confirmed by the validation analysis. Compared to the other drugs, there was a significant difference in the reasons for terminating GA therapy. Conclusion: Small differences were found among GA, IFN beta and teriflunomide therapies, with no significant impact on the final outcome after 2 years. Therefore, in clinical practice, we recommend choosing the drug based on individual potential risk from long-term therapy and on patient preferences and clinical characteristics.
ER  -

PAVELEK, Zbysek, Lukas SOBISEK, Jana SARLAKOVA, Pavel POTUZNIK, Marek PETERKA, Ivana STETKAROVA, Pavel ŠTOURAČ, Jan MARES, Pavel HRADILEK, Radek AMPAPA, Marketa GRUNERMELOVA, Marta VACHOVA, Eva RECMANOVA, Francesco ANGELUCCI, Simona HALUSKOVA a Martin VALIS. Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS. \textit{FRONTIERS IN NEUROLOGY}. LAUSANNE: FRONTIERS MEDIA SA, 2021, roč.~11, JAN 2021, s.~1-12. ISSN~1664-2295. Dostupné z: https://dx.doi.org/10.3389/fneur.2020.593527.

Podrobný výpis o publikaci